Compile Data Set for Download or QSAR
Report error Found 21 Enz. Inhib. hit(s) with all data for entry = 1227
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312960(US9605008, 19 | 3-[1-(2,3-Difluoro-4-methylbenzyl)...)
Affinity DataIC50: 0.25nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312961(US9605008, 20 | 3-[1-(2,3-Difluoro-4-methylbenzyl)...)
Affinity DataIC50: 0.650nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312944(US9605008, 5 | 3-[5-Fluoro-1-(2-fluoro-4-methylben...)
Affinity DataIC50: 1.5nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312945(US9605008, 6 | 3-[1-(2-Fluoro-4-methylbenzyl)-6-me...)
Affinity DataIC50: 2nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312965(US9605008, 26 | 3′-[1-(2,3-Difluoro-4-methyl...)
Affinity DataIC50: 4nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312950(US9605008, 10 | 3-[1-(4-Chloro-2-fluorobenzyl)-6-m...)
Affinity DataIC50: 4.5nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312942(US9605008, 2 | Sodium 3-[1-(2,3-difluorobenzyl)-5-...)
Affinity DataIC50: 5nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312933(US9605008, 1 | 3-[1-(2,3-Difluorobenzyl)-5-fluoro...)
Affinity DataIC50: 5nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312948(US9605008, 9 | 3-[1-(4-Chloro-2-fluorobenzyl)-5-fl...)
Affinity DataIC50: 6nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312958(US9605008, 17 | 3-[5-Fluoro-1-(3-fluoro-4-methylbe...)
Affinity DataIC50: 8nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312959(US9605008, 18 | 3-[1-(3-Fluoro-4-methylbenzyl)-6-m...)
Affinity DataIC50: 10nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312962(US9605008, 22 | 3′-[1-(2-Fluoro-4-methylbenz...)
Affinity DataIC50: 16nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312952(US9605008, 12 | 7,7-Dimethyl-3-[6-methyl-1-(2,3,6-...)
Affinity DataIC50: 21nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312946(US9605008, 7 | 3-[1-(2,4-Difluorobenzyl)-5-fluoro-...)
Affinity DataIC50: 21nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312963(US9605008, 24 | 3′-[1-(2,3-Difluorobenzyl)-6...)
Affinity DataIC50: 21nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312957(US9605008, 16 | 3-[1-(2,6-Difluorobenzyl)-6-methyl...)
Affinity DataIC50: 24nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312951(US9605008, 11 | 3-[5-Fluoro-6-methyl-1-(2,3,6-trif...)
Affinity DataIC50: 27nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312947(US9605008, 8 | 3-[1-(2,4-Difluorobenzyl)-6-methyl-...)
Affinity DataIC50: 34nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312953(US9605008, 13 | 3-[1-(3-Chloro-2-fluorobenzyl)-5-f...)
Affinity DataIC50: 42nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312955(US9605008, 14 | 3-[1-(3-Chloro-2-fluorobenzyl)-6-m...)
Affinity DataIC50: 63nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM312956(US9605008, 15 | 3-[1-(2,6-Difluorobenzyl)-5-fluoro...)
Affinity DataIC50: 67nMAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent